A Non-Inferior Randomized Trial of Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Premenopausal Patients With Hormone-Responsive and HER2-Negative Lymph Node-Negative Breast Cancer

A Non-Inferior Randomized Trial of Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Premenopausal Patients With Hormone-Responsive and HER2-Negative Lymph Node-Negative Breast Cancer

Objectives Neoadjuvant endocrine therapy (NET) has demonstrated efficacy in postmenopausal patients with hormone-responsive and HER2-negative breast cancer. However, few data are available on NET in premenopausal women. This trial was designed to compare the effectiveness of neoadjuvant chemotherapy...

Full description

Saved in:
Bibliographic Details
Main Authors: Chongshan Gu MD, Yingjian He MD, Nan Zhang MD, Yiqiang Liu MD, Jinfeng Li MD, Tianfeng Wang MD, Tie Fan MD, Zhaoqing Fan MD, Tao Ouyang MD
Format: Article
Language:English
Published: SAGE Publishing 2025-04-01
Series:Cancer Control
Online Access:https://doi.org/10.1177/10732748251339958
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/10732748251339958

Similar Items